anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lansoprazole
Trial phase: Phase 2
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 120
Group description: Lansoprazole 15 mg, single dose
Eligibility criteria:
Inclusion Criteria:

Experiencing heartburn in the past month if untreated
Having heartburn that responds to heartburn medication
Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.

Exclusion Criteria:

Having history of erosive esophagitis or gastroesophageal reflux disease (GERD) diagnosed by a physician and confirmed by testing (endoscopy)
Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.

"Other protocol-defined inclusion/exclusion criteria may apply"
Intervention: Capsaicin
Trial phase: Phase 4
ATC code: M02AB01 | M02AB02 | N01BX04
SMILES: COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 126
Group description: One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Eligibility criteria:
Inclusion Criteria:

Grade 1 or Grade 2 ankle sprain

Exclusion Criteria:

Pregnancy or lactation
Intervention: Morphine
Trial phase: Phase 2
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) and 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
Eligibility criteria:
Inclusion Criteria:

- Subjects who were in general good health, experiencing moderate to severe pain following bunionectomy surgery and who were willing to remain confined for approximately 4 days following surgery for study procedures.

Exclusion Criteria:

Subjects who underwent Base wedge osteotomy and/or Long-Z hart bunionectomy procedures
Allergic reaction to study medications
Pregnant or breastfeeding females
Clinically significant lab abnormalities at screening
Positive hepatitis testing at screening
Clinically significant or uncontrolled medical disorders or illness at screening
Active malignancy or chemotherapy
Any history of drug or alcohol abuse/addiction
Known or suspected history of human immunodeficiency virus (HIV); requires treatment with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) or butyrophenones
History of major depressive episode or major psychiatric disorder
Current systemic corticosteroid therapy
Inability to refrain from smoking during or alcohol during stay at investigative site
Intervention: Erlotinib
Trial phase: Phase 2
ATC code: L01EB02 | L01XE03
SMILES: C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation

Erlotinib: Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
Eligibility criteria:
Inclusion Criteria:

WHO 2008 diagnosis of Polycythemia Vera Hemoglobin > 18.5 g/dl for men (16.5 g/dl for women) and presence of JAK2V617F mutation and either bone marrow trilineage myeloproliferation or subnormal serum erythropoietin level Patients may be on active treatment (phlebotomy, aspirin) ECOG performance status 0,1,2,or 3 Adequate hepatic function, adequate renal function

Exclusion Criteria:

Patient with active malignancy Patients with clinically significant cardiac disease within 1 year Opthalmologic or gastrointestinal abnormalities Concurrent cytoreductive therapy is not allowed
Intervention: Melatonin
Trial phase: Phase 2
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Cross-over design for subjects randomized to Melatonin First, Placebo Second
Eligibility criteria:
Inclusion Criteria:

Age 30-79 years.
Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria.
Availability for six months after enrolling in the study.

Exclusion Criteria:

Inability to understand informed consent and to cooperate with study procedures.
Supplemental intake of melatonin.
Current smoking.
Current use of calcium channel blockers.
Current, planned, or recent (12 months) participation in another clinical trial.
Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.

Presence of any of the following diagnosed health conditions:

Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis)
Uncontrolled hypothyroidism or hyperthyroidism
Recent (< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke
Heart failure (New York Heart Association functional class 3 or 4)
On renal dialysis
Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide,
etc.) or an immunodeficiency syndrome
Narcotic or alcohol dependence
Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA.
Shift-workers.
Intervention: Ganetespib
Trial phase: Phase 2
SMILES: CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
Eligibility criteria:
Inclusion Criteria:

Must be at least 18 years of age at the time of study entry
Must have histologically confirmed metastatic and/or unresectable GIST
Must have measurable disease on computed tomography or magnetic resonance imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Must have documented failure (due to either progression or intolerance)of at least prior imatinib and sunitinib. Previous administration of other known heat shock protein 90 (Hsp90) inhibitors is permitted
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Must have acceptable laboratory values as defined in the protocol

Exclusion Criteria:

Known central nervous system metastases
Major surgery within 4 weeks prior to receiving STA-9090
Use of any investigational agents within 2 weeks or 6 half-lives of the agent, whichever is shorter prior to receiving STA-9090
No treatment with chronic immunosuppressants
Must have otherwise adequate health status as defined in the protocol
Left ventricular ejection fraction (LVEF) < than or = 50% at baseline
Baseline corrected QT interval (QTc) > 470 msec
Pregnant or lactating females
Intervention: Icotinib
Trial phase: Phase 3
ATC code: L01EB08
SMILES: C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 200
Group description: Icotinib 125 mg three times daily (375 mg per day) by mouth
Eligibility criteria:
Inclusion Criteria:

Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).
Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.

Exclusion Criteria:

1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.
Intervention: Gefitinib
Trial phase: Phase 3
ATC code: L01EB01 | L01XE02
SMILES: COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 199
Group description: Gefitinib 250 mg every 24 hours by mouth
Eligibility criteria:
Inclusion Criteria:

Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).
Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.

Exclusion Criteria:

1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.
Intervention: Pioglitazone
Trial phase: Phase 4
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.

Pioglitazone: Patients will receive PIO 15 mg/d for one month, then 55 patients will continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. While on PIO, other non-diabetes drugs should not be changed, unless emergency. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited. At baseline, and after 1, and 2 months of treatment the following samples will be taken: 1. Serum for lipid profile, ALT, AST, CK, creatinine, BUN, glucose, HbA1c (the biochemistry laboratory at UTMB) 2. Serum for 6-keto-PGF1a and 15-epi-lipoxin A4 3. Serum for hs-CRP 4. Urine for creatinine, 6-keto-PGF1a and 15-epi-lipoxin A4
Eligibility criteria:
Inclusion Criteria:

1. Men and women > 21 years old with type 2 diabetes Mellitus and otherwise stable medical conditions

Exclusion Criteria:

Serum creatinine >= 1.5 mg/dl and/or renal failure
NYHA class III or IV heart failure
Known intolerance to TZD
Current use of NSAID, COX-2 inhibitors, steroids (oral, topical and inhalation) or immunosuppressive therapy
Aspirin > 162 mg/d
Recent myocardial infarction, ACS, or stroke <=3 months)
Significant comorbid conditions such as: cancer (not cured), end stage renal disease, severe obstructive lung disease, cirrhosis, etc)
Recent (<1 month) infection
Recent CABG or PCI (<3 months)
Use of prostaglandin analogs (i.e., iloprost)
Active inflammatory disease
Current use of TZD
Pregnancy
Osteoporosis or high risk for bone fracture. Use of other antihyperglycemic agents is not an exclusion criterion. HbA1c and glucose levels will not restrict enrollment.
Intervention: Pioglitazone
Trial phase: Phase 4
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
Eligibility criteria:
Inclusion Criteria:

1. Men and women > 21 years old with type 2 diabetes Mellitus and otherwise stable medical conditions

Exclusion Criteria:

Serum creatinine >= 1.5 mg/dl and/or renal failure
NYHA class III or IV heart failure
Known intolerance to TZD
Current use of NSAID, COX-2 inhibitors, steroids (oral, topical and inhalation) or immunosuppressive therapy
Aspirin > 162 mg/d
Recent myocardial infarction, ACS, or stroke <=3 months)
Significant comorbid conditions such as: cancer (not cured), end stage renal disease, severe obstructive lung disease, cirrhosis, etc)
Recent (<1 month) infection
Recent CABG or PCI (<3 months)
Use of prostaglandin analogs (i.e., iloprost)
Active inflammatory disease
Current use of TZD
Pregnancy
Osteoporosis or high risk for bone fracture. Use of other antihyperglycemic agents is not an exclusion criterion. HbA1c and glucose levels will not restrict enrollment.
Intervention: Citalopram
Trial phase: Phase 4
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 49
Group description: Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.

Citalopram: 40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
Eligibility criteria:
Inclusion Criteria:

Male or female
Ages 16-40 years
Schizophrenia, any subtype or Schizophreniform disorder
Treated with any of the following second generation antipsychotics for at least 4 weeks and fewer than 16 weeks: risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, or paliperidone)
Willing to participate in psychoeducation
Sufficient proficiency in English to complete assessments

Exclusion Criteria:

Major depression by DSM-IV criteria
Clinical Global Assessment of Severity of Suicidality of 3 (moderate) or greater.
Calgary Depression Scale for Schizophrenia (CDRS) score of 7 or greater
Serious suicide attempt within three years or ANY suicide attempt for subjects age 16-25.
Current treatment with an MAOI or pimozide
Active alcohol or other substance abuse or dependence within three months
Unstable medical illness
History of SSRI intolerance
Pregnant or nursing
QTc ≥ 500 msec
Intervention: Lovaza
Trial phase: Phase 4
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.

Other Names:

Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules

Lovaza: Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
Eligibility criteria:
Inclusion Criteria:

HIV-infected men and women at least 18 years of age,
On stable HAART for the previous two months and without anticipated changes in their HAART regimen throughout the duration of the study,
Fasting triglycerides > 150 mg/dl and < 2,500 mg/dl
Participants may be on lipid lowering therapy; if on lipid lowering therapy, therapy must be stable for 8 weeks and cannot be changed during the course of the study.
Participants may be on beta blockers (e.g., Atenolol, Metoprolol, Propranolol), and Estrogens (e.g., Estinyl; Estrace; Estraderm), however therapy with these agents must be stable for 8 weeks before starting the study and cannot be altered while on study unless deemed medically necessary by the participant's medical provider and approved by Dr. Wanke.
Female participants of reproductive age must not be pregnant (negative test) or lactating at screening and throughout the trial and agree to use contraception for the course of the trial and 2 months after the trial unless they are surgically sterilized (tubal ligation or hysterectomy), or post-menopausal with no menses for > 1 year.
Ability to provide consent.

Exclusion Criteria:

plasma HIV-1 RNA > 10,000 copies/ml
change in HAART regimen over two months prior to study entry
change in lipid lowering therapy within 2 months (8 weeks)
Pregnancy in female participants
Evidence of liver or renal disease with values of liver enzymes > 5 X upper limit of normal or creatinine > 1.5 X upper limit of normal
presence of active opportunistic infection or malignancy
presence of other inflammatory or end organ disease (, rheumatoid arthritis, active treatment for hepatitis c, or other diseases that may alter inflammatory markers)
routine ingestion of fish oil (individuals who have used fish oil would be reconsidered for study participation if they discontinue use of fish oil for 8 weeks and TG levels remain elevated).
Allergic to fish or Lovaza
BMI >35
Intervention: Sunitinib
Trial phase: Phase 2
ATC code: L01EX01
SMILES: CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Sunitinib: Sunitinib 37.5 mg daily X 16 weeks
Eligibility criteria:
Inclusion Criteria:

Histologic diagnosis of bladder carcinoma (>50% urothelial carcinoma)
Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy
Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0
ECOG performance status of 0-1 (Appendix 2).
No evidence of metastases within 4 weeks of registration
Adequate organ and marrow function obtained within 14 days of registration

Exclusion Criteria:

Severe or uncontrolled acute or chronic medical or psychiatric condition
Prior antiangiogenic therapy
Prior pelvic radiation for bladder cancer
Intervention: Dapagliflozin
Trial phase: Phase 3
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 482
Group description: Dapagliflozin 10 mg plus usual care
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus.
Cardiovascular disease
Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment

Exclusion Criteria:

Patients with type 1 diabetes or diabetes insipidus
Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
Any clinically significant illness, which would compromise the patient's safety and their participation in the study
Intervention: Pitavastatin
Trial phase: Phase 4
ATC code: C10AA08
SMILES: O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
Eligibility criteria:
Inclusion Criteria:

Subject is an adult male or female subject aged 18 years or older. Females of childbearing potential must have a negative pregnancy test before beginning the study.
Subject has no clinically significant medical conditions (other than renal impairment and associated diseases, such as hypertension, diabetes, and dyslipidemia, for subjects in Group A) as determined by medical history, physical examination, 12-lead ECG, clinical laboratory results (hematology, serum chemistry, and urinalysis [if able to pass urine]), and serology results (hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus types 1 and 2 antibody). Subjects with positive results for hepatitis C virus but who have normal liver enzymes will not be excluded. Any subjects who have impaired hepatic function that will potentially affect drug metabolism should be excluded.
Subject provides written informed consent before any study-specific evaluation is performed.
Subject is able and willing to comply with the protocol and study procedures.

Exclusion Criteria:

Subject is on maintenance hemodialysis.
Subject has a BMI of >37 kg/m2.
Intervention: Pitavastatin
Trial phase: Phase 4
ATC code: C10AA08
SMILES: O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
Eligibility criteria:
Inclusion Criteria:

Subject is an adult male or female subject aged 18 years or older. Females of childbearing potential must have a negative pregnancy test before beginning the study.
Subject has no clinically significant medical conditions (other than renal impairment and associated diseases, such as hypertension, diabetes, and dyslipidemia, for subjects in Group A) as determined by medical history, physical examination, 12-lead ECG, clinical laboratory results (hematology, serum chemistry, and urinalysis [if able to pass urine]), and serology results (hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus types 1 and 2 antibody). Subjects with positive results for hepatitis C virus but who have normal liver enzymes will not be excluded. Any subjects who have impaired hepatic function that will potentially affect drug metabolism should be excluded.
Subject provides written informed consent before any study-specific evaluation is performed.
Subject is able and willing to comply with the protocol and study procedures.

Exclusion Criteria:

Subject is on maintenance hemodialysis.
Subject has a BMI of >37 kg/m2.
Intervention: Lesogaberan
Trial phase: Phase 2
SMILES: NC[C@@H](F)C[PH](=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: a morning and an evening dose of AZD3355 30 mg
Eligibility criteria:
Inclusion Criteria:

Provide informed consent
History of GERD with persistent symptoms despite treatment with PPI
Otherwise normal physical health

Exclusion Criteria:

History of GERD with symptoms that has not improved at all during treatment with PPI
Prior surgery of the upper gastrointestinal tract
History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD
Intervention: Lesogaberan
Trial phase: Phase 2
SMILES: NC[C@@H](F)C[PH](=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: a morning and an evening dose of AZD3355 90 mg
Eligibility criteria:
Inclusion Criteria:

Provide informed consent
History of GERD with persistent symptoms despite treatment with PPI
Otherwise normal physical health

Exclusion Criteria:

History of GERD with symptoms that has not improved at all during treatment with PPI
Prior surgery of the upper gastrointestinal tract
History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD
Intervention: Lesogaberan
Trial phase: Phase 2
SMILES: NC[C@@H](F)C[PH](=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: a morning and an evening dose of AZD3355 120 mg
Eligibility criteria:
Inclusion Criteria:

Provide informed consent
History of GERD with persistent symptoms despite treatment with PPI
Otherwise normal physical health

Exclusion Criteria:

History of GERD with symptoms that has not improved at all during treatment with PPI
Prior surgery of the upper gastrointestinal tract
History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD
Intervention: Lesogaberan
Trial phase: Phase 2
SMILES: NC[C@@H](F)C[PH](=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: a morning and an evening dose of AZD3355 240 mg
Eligibility criteria:
Inclusion Criteria:

Provide informed consent
History of GERD with persistent symptoms despite treatment with PPI
Otherwise normal physical health

Exclusion Criteria:

History of GERD with symptoms that has not improved at all during treatment with PPI
Prior surgery of the upper gastrointestinal tract
History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD